# Eikon Therapeutics, Inc.

**EIKN**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001861123

# None


### No letter

0 of 14 inputs computable; 7 are required, with a score in every sleeve

**Scoreboard**


| | |
|---|---|
| **Warnings** | thin data<br>not computable: dilution, short runway, degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 0 of 14 |
| **Graded from** | filings received through n/a<br>None days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $5.98<br>2026-11-13; market equity $324.0M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 30, 2026*

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | |
|---|---|---|
| *one or more required annual facts are missing* | | |
| Accruals ratio | not computable | (6.6%) |
| *one or more required annual facts are missing* | | |
| Gross margin stability, five years | not computable | 2.8 pts |
| *five annual gross margins are required; found 0* | | |
| **Solvency** | | |
| Twelve-month failure probability | not computable | 0.08% |
| *four consecutive discrete net-income quarters are required; found 3* | | |
| Altman Z double-prime | not computable | (0.31) |
| *one or more required annual facts are missing* | | |
| Net debt to EBITDA | not computable | 1.82x |
| *one or more required annual facts are missing* | | |
| Interest coverage | not computable | (4.51x) |
| *one or more required annual facts are missing* | | |
| Current ratio | not computable | 2.96x |
| *one or more required annual facts are missing* | | |
| **Growth and financing** | | |
| Revenue growth, three-year compound | not computable | 10.1% |
| *four annual observations are required; found 0* | | |
| Free cash flow growth, three-year compound | not computable | 11.0% |
| *four consecutive annual FCF observations are required; found 0* | | |
| Reinvestment rate | not computable | 37.1% |
| *one or more required annual facts are missing* | | |
| Asset growth, three years | not computable | 2.3% |
| *four annual observations are required; found 0* | | |
| Net share issuance, one year | not computable | 2.4% |
| *two annual share counts are required; found 0* | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 0 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | not computable | (1.5%) | |
| Distance from 52-week high | (63.2%) | (32.0%) | 18 |
| EBIT to enterprise value | not computable | (1.8%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | 1.19 | 0.29 | 88 |
| Sales to price | not computable | 0.29 | |
| Composite equity issuance, five years | not computable | 19.1% | |
| Relative strength against the sector, log excess return | not computable | (0.18) | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 4 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $4.2M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|